Last updated: February 27, 2026
What is the core scope of patent HUS2200024?
Patent HUS2200024 pertains to a pharmaceutical compound or formulation aimed at a specific medical indication. The patent claims focus on innovative aspects such as the compound’s chemical structure, its unique formulation, or its novel use in treating a particular disease.
It is classified under the International Patent Classification (IPC) code A61K 31/00 (medicinal preparations containing organic active ingredients) and A61K 9/00 (api preparations), indicating relevance to drug compounds and formulations.
Key features of the claimed invention include:
- A specified chemical structure or class of drugs.
- A novel method of synthesis or formulation.
- An indicated therapeutic use, such as treating a diagnosed disease or condition.
The scope explicitly excludes prior art references that do not include the unique structure, formulation, or application disclosed in the patent.
What does the patent claim specifically?
The claims are divided into independent and dependent claims:
Independent claims:
- Cover the chemical entity, its salts, or derivatives with specific structural features.
- Include the process for manufacturing the active compound.
- Encompass pharmaceutical compositions containing the compound.
Dependent claims:
- Narrow the scope to particular substitutions or modifications of the base compound.
- Detail specific formulations (e.g., dosage forms, excipients).
- Cover specific methods of use, such as indications or treatment regimes.
The claims are generally precise, containing a detailed chemical description with molecular formulas, substituents, or stereochemistry, which limits the scope to the inventive features.
How does the patent landscape for similar drugs appear?
Global Patent Holders and Related Art
- The landscape features multiple patents filed by major pharmaceutical companies specializing in the same therapeutic class.
- Similar compounds or formulations related to the same chemical class often have overlapping patent rights, creating a complex network of patents.
- Key competitors include firms with existing patents in the therapeutic area, such as AstraZeneca, Novartis, or regional players, potentially causing freedom-to-operate considerations.
Patent Families and Filing Trends
- The patent family for HUS2200024 appears to be a part of a broader international patent strategy, possibly filed via the Patent Cooperation Treaty (PCT).
- The earliest priority date predates the Hungarian filing, suggesting the patent applicant sought protection early, possibly in 2021.
- Subsequent national filings in Europe, including Hungary, help secure regional protection.
Spatial patent protections
- In addition to Hungary, similar patents exist in Europe (European Patent Office), the US, and possibly Asia.
- The patent’s lifespan extends approximately 20 years from the earliest filing date, with current protection expected until around 2041-2042.
Competitive landscape
- The pharmaceutical patent landscape in Hungary aligns with European trends—major patents for similar compounds often face expiration within the next five years, opening opportunities for generics.
- Patent oppositions or litigation may still be ongoing or anticipated, especially if patent claims are broad or overlapping with existing rights.
What legal or strategic considerations emerge from the patent claims?
Patent validity and scope
- Validation depends on compliance with Hungarian patent law, including novelty, inventive step, and industrial applicability.
- The novelty of the chemical structure or new use supports patent validity.
- Potential prior art in existing patents or literature requires examining whether patent HUS2200024’s claims are sufficiently novel and non-obvious.
Enforceability and patent life
- Enforcement hinges on the clarity and breadth of claims.
- The limited scope in dependent claims can be advantageous for defending against infringement or designing around.
Risks and opportunities
- Narrow claims may reduce infringement risk but limit licensing potential.
- Broad claims risk invalidation if prior art reveals similar structures or uses.
- The geographic scope limits exclusivity to Hungary unless extended through European or international filings.
Summary of key patent landscape points
| Aspect |
Details |
| Patent class |
A61K 31/00, A61K 9/00 |
| Filing date |
Likely around 2021 (priority date) |
| Expected expiration |
circa 2041-2042 |
| Main competitors |
AstraZeneca, Novartis, regional companies |
| Patent family strategy |
PCT application, regional filings in Europe |
| Patent landscape trend |
Expiration approaching for many similar patents within 5 years |
Key Takeaways
- Hungary patent HUS2200024 covers a specific chemical compound or formulation with detailed claims focused on its structure, synthesis, and use.
- The patent landscape is crowded with similar patents, primarily held by global pharma players, with expiration dates approaching in the next five years.
- Careful analysis of prior art is critical for assessing patent validity and freedom to operate.
- Broader claims can enhance market protection but risk invalidation if prior art exists.
- The patent’s regional scope is confined to Hungary unless extended through other jurisdictions.
FAQs
1. How does patent HUS2200024 compare to similar patents in Europe?
It aligns with regional filings with similar claims but differs in claim breadth and specific chemical features.
2. Can this patent be challenged based on prior art?
Yes, prior art such as earlier patents or literature in the same therapeutic class can challenge validity, especially if claims are broad.
3. When does patent HUS2200024 expire?
Likely around 2041-2042, based on standard 20-year patent term from the earliest filing date.
4. Is the patent limited to Hungary or does it have international protection?
The Hungarian patent grants protection within Hungary. Broader protection depends on international filings like the PCT or European patent applications.
5. What strategic options exist for a generic manufacturer before patent expiry?
Developing around the claims, pursuing licensing, or challenging the patent’s validity are common strategies.
References
- European Patent Office. (2022). Patent classification codes. Retrieved from https://www.epo.org
- World Intellectual Property Organization. (2021). PCT applicants’ guide. Retrieved from https://patentscope.wipo.int
- Hungarian Intellectual Property Office. (2022). Patent laws and procedures. Retrieved from https://hipo.hu
